Flomoxef Sodium is a β-lactam inhibitor and member of the oxacephem family and exhibits antibiotic properties. It has been used for respiratory infections and bone diseases (ie osteoporosis). It was synthesized in 1982 by Shionogi & Co, Osaka, Japan in order to overcome disulfiram actions.
|Mechanism of Action||Flomoxef Sodium is a β-lactam inhibitor that acts by inhibiting cell-wall synthesis. This is performed by binding to penicillin-binding proteins which prevents the transpeptidation step of peptidoglycan synthesis in bacterial cell walls, leading to the inhibition of cell-wall biosynthesis.|
|Spectrum||Flomoxef Sodium is effective for Gram-negative and Gram-positive bacteria including MRSA. It is also effective for Nocardia.|
|Microbiology Applications||Flomoxef is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-positive and Gram-negative microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options. Representative MIC values include:
For a representative list of Flomoxef MIC values, click here.
Gilman AG, Rall TW, and Nies AS (eds) (1990) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed. Macmillan Publishing Co, New York, NY
Ito M and Ishigami T (1991) The meaning of the development of Flomoxef and clinical experience in Japan. Infection 19 (suppl 5):S253-S257 PMID 1783441
Kitahara T et al (2004) Antimicrobial activity of saturated fatty acids and fatty amines against Methicillin-resistant Staphylococcus aureus. Biol. Pharm. Bull. 27(9):1321-1326 PMID 15340213
Ruckdeschel G and Eder W (1988) Comparative in vitro activity of the new oxacephem antibiotic, Flomoxef. Eur. J. Clin. Microbiol. Infect. Dis. 7:687-691 PMID 3143586
Tsuji T, Satoh H, Narisada M, Hamashima Y and Yoshida T (1985) Synthesis and antibacterial activity of 6315-S, a new member of the oxacephem antibiotic. J. Antibiotics 38 (4):466-476 PMID 4008339
Yazawa K, Mikami Y, Uno J, Otozai K, Arai T (1989) In-vitro activity of Flomoxef, a new oxacephem group antibiotic, against Nocardia in comparison with other cephalosporins. J. Antimicrob. Chemother. 24(6):921-925 PMID 2621177